$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

$gthp Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000147793223003493 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$44.00K	$22.00K	$5.000K
YoY Change	780.0%	340.0%
Cost Of Revenue	$33.00K	$9.000K	$1.000K
YoY Change	3200.0%	800.0%
Gross Profit	$11.00K	$13.00K	$4.000K
YoY Change	175.0%	225.0%
Gross Profit Margin	25.0%	59.09%	80.0%
Selling, General & Admin	$1.450M	$849.0K	$426.0K
YoY Change	103.65%	99.3%	-47.21%
% of Gross Profit	13181.82%	6530.77%	10650.0%
Research & Development	$66.00K	$7.000K	$21.00K
YoY Change	633.33%	-66.67%	31.25%
% of Gross Profit	600.0%	53.85%	525.0%
Depreciation & Amortization	$3.000K	$2.000K	$0.00
YoY Change
% of Gross Profit	27.27%	15.38%	0.0%
Operating Expenses	$1.516M	$856.0K	$447.0K
YoY Change	110.26%	91.5%	-45.69%
Operating Profit	-$1.505M	-$843.0K	-$443.0K
YoY Change	109.9%	90.29%	-46.17%
Interest Expense	$69.00K	$66.00K	$101.0K
YoY Change	-73.05%	-34.65%	-28.37%
% of Operating Profit
Other Income/Expense, Net	-$52.00K	-$26.00K	$2.000K
YoY Change	-75.12%	-1400.0%
Pretax Income	-$1.557M	-$869.0K	-$507.0K
YoY Change	68.14%	71.4%	-1.93%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.557M	-$869.0K	-$507.0K
YoY Change	68.14%	71.4%	-1.93%
Net Earnings / Revenue	-3538.64%	-3950.0%	-10140.0%
Basic Earnings Per Share	-$0.03	-$0.02	-$0.05
Diluted Earnings Per Share	-$0.03	-$0.02	-$0.05
COMMON SHARES
Basic Shares Outstanding	51.01M shares	50.51M shares
Diluted Shares Outstanding	50.97M shares	49.30M shares	20.68M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.358M	$1.837M	$725.0K
YoY Change	204.48%	153.38%	-41.86%
Cash & Equivalents	$1.358M	$1.837M	$725.0K
Short-Term Investments
Other Short-Term Assets	$91.00K	$121.0K	$453.0K
YoY Change	54.24%	-73.29%	1061.54%
Inventory	$573.0K	$585.0K	$570.0K
Prepaid Expenses
Receivables	$7.000K	$7.000K	$39.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.029M	$2.550M	$1.787M
YoY Change	83.95%	42.7%	-6.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$36.00K	$40.00K	$28.00K
YoY Change	-20.0%	42.86%	-93.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$17.00K	$17.00K	$17.00K
YoY Change	0.0%	0.0%	-5.56%
Total Long-Term Assets	$319.0K	$342.0K	$400.0K
YoY Change	-20.25%	-14.5%	-10.31%
TOTAL ASSETS
Total Short-Term Assets	$2.029M	$2.550M	$1.787M
Total Long-Term Assets	$319.0K	$342.0K	$400.0K
Total Assets	$2.348M	$2.892M	$2.187M
YoY Change	56.22%	32.24%	-7.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.128M	$2.191M	$2.556M
YoY Change	-11.48%	-14.28%	-0.31%
Accrued Expenses	$971.0K	$928.0K	$999.0K
YoY Change	-19.49%	-7.11%	-78.73%
Deferred Revenue
YoY Change
Short-Term Debt	$1.240M	$248.0K	$788.0K
YoY Change	228.04%	-68.53%	-39.2%
Long-Term Debt Due	$0.00	$0.00	$67.00K
YoY Change	-100.0%	-100.0%	-72.65%
Total Short-Term Liabilities	$4.936M	$4.003M	$5.449M
YoY Change	-17.68%	-26.54%	-40.96%
LONG-TERM LIABILITIES
Long-Term Debt	$525.0K	$1.519M	$1.420M
YoY Change	-46.75%	6.97%	145.25%
Other Long-Term Liabilities	$202.0K	$225.0K	$307.0K
YoY Change	-29.62%	-26.71%	-37.22%
Total Long-Term Liabilities	$727.0K	$1.744M	$1.727M
YoY Change	-42.89%	0.98%	61.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.936M	$4.003M	$5.449M
Total Long-Term Liabilities	$727.0K	$1.744M	$1.727M
Total Liabilities	$5.663M	$5.747M	$7.176M
YoY Change	-22.09%	-19.91%	-30.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$149.9M	-$148.3M	-$143.4M
YoY Change	3.8%	3.41%
Common Stock	$3.438M	$3.438M	$3.410M
YoY Change	0.64%	0.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$132.0K	$132.0K
YoY Change	0.0%
Treasury Stock Shares
Shareholders Equity	-$3.315M	-$2.855M	-$4.988M
YoY Change
Total Liabilities & Shareholders Equity	$2.348M	$2.892M	$2.187M
YoY Change	56.22%	32.24%	-7.41%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.557M	-$869.0K	-$507.0K
YoY Change	68.14%	71.4%	-1.93%
Depreciation, Depletion And Amortization	$3.000K	$2.000K	$0.00
YoY Change
Cash From Operating Activities	-$438.0K	-$499.0K	-$179.0K
YoY Change	25.5%	178.77%	-44.06%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$14.00K
YoY Change		-100.0%	1300.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$14.00K
YoY Change	-100.0%	-100.0%	1300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-41.00K	$23.00K	$275.0K
YoY Change	-147.13%	-91.64%	-80.16%
NET CHANGE
Cash From Operating Activities	-438.0K	-$499.0K	-$179.0K
Cash From Investing Activities	0.000	$0.00	-$14.00K
Cash From Financing Activities	-41.00K	$23.00K	$275.0K
Net Change In Cash	-479.0K	-$476.0K	$82.00K
YoY Change	71.68%	-680.49%	-92.3%
FREE CASH FLOW
Cash From Operating Activities	-$438.0K	-$499.0K	-$179.0K
Capital Expenditures		$0.00	$14.00K
Free Cash Flow		-$499.0K	-$193.0K
YoY Change		158.55%	-39.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	725000	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	39000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	13000	usd
CY2023Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	29000	usd
CY2023Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1000	usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000924515
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	48000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	818000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48596000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50814000	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	48595715	shares
CY2022Q4	us-gaap	Common Unit Outstanding CommonUnitOutstanding	48595715	shares
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.49
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2023Q1	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	0	usd
CY2023Q1	gthp	Outstanding Principal Longterm Debt OutstandingPrincipalLongtermDebt	0	usd
CY2023Q1	gthp	Accrued Interest AccruedInterest	0	usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Entity File Number EntityFileNumber	000-22179
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	GUIDED THERAPEUTICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2029543
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5835 Peachtree Corners East
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite B
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Norcross
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30092
CY2023Q1	dei	City Area Code CityAreaCode	770
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	242-8723
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51010579	shares
CY2023Q1	us-gaap	Revenues Revenues	22000	usd
CY2022Q1	us-gaap	Revenues Revenues	5000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	4000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	73000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	40000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	776000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	386000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	856000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	447000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-843000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-443000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	66000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	101000	usd
CY2023Q1	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	5000	usd
CY2022Q1	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-6000	usd
CY2022Q1	gthp	Gain From Extinguishment Of Debt GainFromExtinguishmentOfDebt	41000	usd
CY2023Q1	us-gaap	Other Income OtherIncome	0	usd
CY2022Q1	us-gaap	Other Income OtherIncome	2000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-64000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-869000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-507000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-869000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-507000	usd
CY2023Q1	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	-65000	usd
CY2022Q1	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	0	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	35000	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	548000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-969000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1055000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	49297000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	20683000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49297000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20683000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2883000	usd
CY2023Q1	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	222000	usd
CY2023Q1	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	6000	usd
CY2023Q1	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	8000	usd
CY2023Q1	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	53000	usd
CY2023Q1	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	20000	usd
CY2023Q1	gthp	Conversion Of Series E Preferred Stock To Common Stock Amount ConversionOfSeriesEPreferredStockToCommonStockAmount	0	usd
CY2023Q1	gthp	Conversion Of Series F Preferred Stock To Common Stock Amount ConversionOfSeriesFPreferredStockToCommonStockAmount	0	usd
CY2023Q1	gthp	Conversion Of Series F2 Preferred Stock To Common Stock Amount ConversionOfSeriesF2PreferredStockToCommonStockAmount	0	usd
CY2023Q1	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	59000	usd
CY2023Q1	gthp	Issuance Of Common Stock To Consultants Amount IssuanceOfCommonStockToConsultantsAmount	116000	usd
CY2023Q1	gthp	Stockbasedcompensation Stockbasedcompensation	107000	usd
CY2023Q1	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	341000	usd
CY2023Q1	gthp	Impact Of Warrant Exchanges ImpactOfWarrantExchanges	0	usd
CY2023Q1	gthp	Accruedpreferreddividends Accruedpreferreddividends	-35000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-869000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2855000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-5445000	usd
CY2022Q1	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	716000	usd
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	15000	usd
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	8000	usd
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	105000	usd
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	64000	usd
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	81000	usd
CY2022Q1	gthp	Issuance Of Common Stock For Series F And Series F2 One Time15 Dividends Amount IssuanceOfCommonStockForSeriesFAndSeriesF2OneTime15DividendsAmount	399000	usd
CY2022Q1	gthp	Conversion Of Series E Preferred Stock To Common Stock Amount ConversionOfSeriesEPreferredStockToCommonStockAmount	0	usd
CY2022Q1	gthp	Conversion Of Series F Preferred Stock To Common Stock Amount ConversionOfSeriesFPreferredStockToCommonStockAmount	0	usd
CY2022Q1	gthp	Stockbasedcompensation Stockbasedcompensation	44000	usd
CY2022Q1	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	79000	usd
CY2022Q1	gthp	Accruedpreferreddividends Accruedpreferreddividends	-548000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-507000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4989000	usd
CY2023Q1	gthp	Expense For Common Stock And Warrants Issued To Consultants ExpenseForCommonStockAndWarrantsIssuedToConsultants	457000	usd
CY2022Q1	gthp	Expense For Common Stock And Warrants Issued To Consultants ExpenseForCommonStockAndWarrantsIssuedToConsultants	79000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	usd
CY2023Q1	gthp	Common Stock Issued For Payment Of Interest CommonStockIssuedForPaymentOfInterest	59000	usd
CY2022Q1	gthp	Common Stock Issued For Payment Of Interest CommonStockIssuedForPaymentOfInterest	81000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	88000	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	592000	usd
CY2023Q1	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	5000	usd
CY2023Q1	gthp	Working Capital WorkingCapital	1500000	usd
CY2023Q1	gthp	Accumulated Deficit AccumulatedDeficit	-148300	shares
CY2023Q1	gthp	Net Loss Including Preferred Dividend NetLossIncludingPreferredDividend	1000000.0	usd
CY2023Q1	gthp	Proceeds From Sale Of Common Stock ProceedsFromSaleOfCommonStock	195000	usd
CY2022	us-gaap	Proceeds From Sale Of Trust Assets To Pay Expenses ProceedsFromSaleOfTrustAssetsToPayExpenses	3200000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	495000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1292000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1260000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	73000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	68000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	38000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	38000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	818000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	818000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	585000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	548000	usd
CY2023Q1	gthp	Subtotal Subtotal	1792000	usd
CY2022Q4	gthp	Subtotal Subtotal	1792000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1752000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1750000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	48172	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	6312	usd
CY2023Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	399000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	444000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	178000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	285000	usd
CY2023Q1	gthp	Accrued Stock Subscription Payable AccruedStockSubscriptionPayable	10000	usd
CY2022Q4	gthp	Accrued Stock Subscription Payable AccruedStockSubscriptionPayable	36000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	112000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	189000	usd
CY2023Q1	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	44000	usd
CY2022Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	41000	usd
CY2023Q1	us-gaap	Dividends Payable Current DividendsPayableCurrent	178000	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	231000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	7000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	21000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	928000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1247000	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	487882	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	509101	usd
CY2023Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	55314	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	48172	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7142	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	54484	usd
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	65600000	usd
CY2023Q1	us-gaap	Premiums Percentage Assumed To Net PremiumsPercentageAssumedToNet	0.50	pure
CY2019Q4	gthp	Derivative Liability Bifurcated Conversion Option Actus Loan Amount DerivativeLiabilityBifurcatedConversionOptionActusLoanAmount	326016	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	-5000	usd
CY2023Q1	gthp	Options Granted Exercisable Term OptionsGrantedExercisableTerm	four years
CY2023Q1	gthp	Options Granted Expiration Term OptionsGrantedExpirationTerm	ten years
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Shares Issued SharesIssued	50814258	shares
CY2023Q1	us-gaap	Common Unit Outstanding CommonUnitOutstanding	48595715	shares
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	2218543	shares
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	2218543	shares
CY2022Q4	gthp	Share Outstanding ShareOutstanding	48595715	shares
CY2023Q1	gthp	Share Outstanding ShareOutstanding	50814258	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	35586980	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	1873750	shares
CY2023Q1	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued	0.25
CY2023Q1	gthp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExchanged	-1025000	usd
CY2023Q1	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options For Exchange In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExchangeInPeriodWeightedAverageExercisePrice	0.25
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	7410000	shares
CY2023Q1	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceExpired	0.20
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	973750	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.20
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	28051980	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.54
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y5M19D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.404	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.038	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2023Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.10	pure
CY2023Q1	gthp	Vesting Period Description VestingPeriodDescription	One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on May 10, 2023.
CY2023Q1	gthp	Vesting Period Description VestingPeriodDescription	One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on June 7, 2023.
CY2023Q1	gthp	Stock Based Compensation Expense StockBasedCompensationExpense	107068	usd
CY2022Q1	gthp	Stock Based Compensation Expense StockBasedCompensationExpense	43912	usd
CY2023Q1	gthp	Outstanding At Beginning Of Year OutstandingAtBeginningOfYear	1500000	shares
CY2023Q1	gthp	Weighted Average Remaining Contractual Life Beginning WeightedAverageRemainingContractualLifeBeginning	P7Y6M
CY2022Q4	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
CY2023Q1	gthp	Options Granted OptionsGranted	1025000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.26
CY2023Q1	gthp	Share Based Compensation Arrangement By Share Based Payment Award Option Forfeiture In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeitureInPeriod	-186364	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.31
CY2023Q1	gthp	Outstanding End OutstandingEnd	2338636	shares
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.41
CY2023Q1	gthp	Weighted Average Remaining Contractual Life Ending WeightedAverageRemainingContractualLifeEnding	P6Y10M24D
CY2023Q1	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
CY2023Q1	gthp	Number Of Shares Exercisable NumberOfSharesExercisable	1656205	shares
CY2023Q1	gthp	Weighted Average Exercise Price Per Share Exercisable WeightedAverageExercisePricePerShareExercisable	0.45
CY2023Q1	gthp	Weighted Average Remaining Contractual Life Exercisable WeightedAverageRemainingContractualLifeExercisable	P5Y9M18D
CY2023Q1	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	0	usd
CY2022Q1	gthp	Outstanding End OutstandingEnd	1500000	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.49
CY2022Q1	gthp	Weighted Average Remaining Contractual Life Exercisable WeightedAverageRemainingContractualLifeExercisable	P8Y3M18D
CY2022Q1	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	240	usd
CY2022Q1	gthp	Number Of Shares Exercisable NumberOfSharesExercisable	1045227	shares
CY2022Q1	gthp	Weighted Average Exercise Price Per Share Exercisable WeightedAverageExercisePricePerShareExercisable	0.49
CY2022Q1	gthp	Weighted Average Remaining Contractual Life Ending WeightedAverageRemainingContractualLifeEnding	P8Y3M18D
CY2022Q1	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	167000	usd
CY2023Q1	gthp	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	193947	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.26
CY2023Q1	gthp	Expected Term Years ExpectedTermYears	P10Y
CY2023Q1	gthp	Fair Value Assumption Expected Volatility Rate FairValueAssumptionExpectedVolatilityRate	3.664	pure
CY2023Q1	gthp	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.038	pure
CY2023Q1	gthp	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0.000	pure
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	285000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	303000	usd
CY2023Q1	gthp	Operating Lease Liability One OperatingLeaseLiabilityOne	307000	usd
CY2022Q4	gthp	Operating Lease Liability One OperatingLeaseLiabilityOne	325000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	84000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	115000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	118000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	50000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	367000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60000	usd
CY2023Q1	gthp	Operating Lease Liabilities OperatingLeaseLiabilities	307000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P3Y2M12D
CY2022Q1	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P3Y4M24D
CY2023Q1	gthp	Weighted Average Discount Rateoperating Lease WeightedAverageDiscountRateoperatingLease	0.114	pure
CY2022Q1	gthp	Weighted Average Discount Rateoperating Lease WeightedAverageDiscountRateoperatingLease	0.114	pure
CY2016Q2	gthp	Royalty Percent RoyaltyPercent	0.20	pure
CY2020Q1	gthp	Warrants Broken Into Four Tranches WarrantsBrokenIntoFourTranches	1250000	shares
CY2020Q1	us-gaap	Share Price SharePrice	0.25
CY2023Q1	gthp	Estimated Fair Value Of The Warrants EstimatedFairValueOfTheWarrants	800000	shares
CY2023Q1	gthp	Recognized Expenses For The Warrants RecognizedExpensesForTheWarrants	45172	usd
CY2019Q3	gthp	Consideration Received ConsiderationReceived	885144	usd
CY2019Q3	gthp	Escrow Agent Rate Per Share EscrowAgentRatePerShare	1.90
CY2022Q3	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	123889	usd
CY2022Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	11409	usd
CY2022Q3	gthp	Accrued Interest Rate AccruedInterestRate	0.050	pure
CY2023Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-05-04
CY2023Q1	us-gaap	Notes Payable NotesPayable	22770	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	56569	usd
CY2023Q1	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	23000	usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	58000	usd
CY2022Q4	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	619	usd
CY2019Q4	us-gaap	Convertible Debt ConvertibleDebt	240000	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.24	pure
CY2023Q1	gthp	Convertible Debt Conversion Price Description ConvertibleDebtConversionPriceDescription	variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date
CY2019Q4	us-gaap	Share Price SharePrice	0.04
CY2019Q4	gthp	Variable Conversion Price VariableConversionPrice	0.15
CY2023Q1	gthp	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	1228183	usd
CY2022Q3	gthp	Early Repayment Of Senior Debt Penalty EarlyRepaymentOfSeniorDebtPenalty	350000	usd
CY2022Q3	gthp	Default Premiums DefaultPremiums	281256	usd
CY2022Q3	gthp	Interest Payable InterestPayable	91555	usd
CY2022Q3	gthp	Amount Reduce After Exchange AmountReduceAfterExchange	710911	usd
CY2022Q3	gthp	Warrant Exchange WarrantExchange	8775000	shares
CY2022Q3	gthp	Debt Instrument Default Penalty Forgiven DebtInstrumentDefaultPenaltyForgiven	225444	usd
CY2023Q1	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130000	usd
CY2022Q4	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130000	usd
CY2023Q1	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-33000	usd
CY2022Q4	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-40000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	115000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	140000	usd
CY2023Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	982000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	950000	usd
CY2022Q4	gthp	Outstanding Principal Longterm Debt OutstandingPrincipalLongtermDebt	17052	usd
CY2022Q4	gthp	Accrued Interest AccruedInterest	5139	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-969000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1055000	usd
CY2023Q1	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	49297000	shares
CY2022Q1	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	20683000	shares
CY2023Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.02
CY2022Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.05
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	49297000	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20683000	shares
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.02
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05

Files In Submission

Name	View Source	Status
0001477932-23-003493-index-headers.html	Edgar Link	pending
0001477932-23-003493-index.html	Edgar Link	pending
0001477932-23-003493.txt	Edgar Link	pending
0001477932-23-003493-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gthp-20230331.xsd	Edgar Link	pending
gthp_10q.htm	Edgar Link	pending
gthp_ex101.htm	Edgar Link	pending
gthp_ex102.htm	Edgar Link	pending
gthp_ex103.htm	Edgar Link	pending
gthp_ex31.htm	Edgar Link	pending
gthp-20230331_def.xml	Edgar Link	unprocessable
gthp-20230331_cal.xml	Edgar Link	unprocessable
gthp-20230331_lab.xml	Edgar Link	unprocessable
gthp-20230331_pre.xml	Edgar Link	unprocessable
gthp_10q_htm.xml	Edgar Link	completed
gthp_ex32.htm	Edgar Link	pending
gthp_ex41.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

2023 Q2 Form 10-Q Financial Statement

#000147793223003493 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP GUIDED THERAPEUTICS INC Stock $gthp

2023 Q2 Form 10-Q Financial Statement

#000147793223003493 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp